Merck & Co., Inc. is 78.2x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($293.16 B vs $3.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KNSA | MRK |
|---|---|---|
| Market cap | $3.75 B | $293.16 B |
| US-listed rank | #1625 | #44 |
| Revenue (latest FY) | $677.56M | $65.01B |
| Net income (latest FY) | $59.01M | $18.25B |
| Net margin | 8.7% | 28.1% |
| P/E (trailing FY) | 63.6 | 16.1 |
| SEC filings | 733 | 996 |
Merck & Co., Inc. is 78.2x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($293.16 B vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and Merck & Co., Inc., or browse the full rankings.